论文部分内容阅读
目的研究汉防己甲素(Tet)对晚期非小细胞肺癌的放射增敏作用及不良反应。方法经病理学或细胞学确诊的82例晚期非小细胞肺癌患者,首程治疗均给以放疗,分为3组:Tet组、紫杉醇组及单纯放疗组。Tet组30例从放疗第1天开始服用Tet,每天3次,每次40mg,直至放疗结束。紫杉醇组29例在放疗期间每周静脉滴注紫杉醇1次,每次60mg。单纯放疗组23例仅行放疗。结果 Tet与紫杉醇有相同的放疗增敏作用,两者总有效率均高于单纯放疗组,差异有统计学意义(P<0.05)。放射性肺炎总发生率Tet组明显低于其余两组(P<0.05)。Tet组一年内无病生存率高于其他两组。结论 Tet有紫杉醇相当的放疗增敏作用,并能减轻放疗不良反应。
Objective To study the radiosensitization and adverse reactions of Tetralone on advanced non-small cell lung cancer. Methods 82 cases of advanced non-small cell lung cancer diagnosed by pathology or cytology were treated with radiotherapy in the first course of treatment and were divided into three groups: Tet group, paclitaxel group and radiotherapy alone group. Tet group from the first day of radiotherapy 30 patients take Tet, 3 times a day, each 40mg, until the end of radiotherapy. Paclitaxel group, 29 cases of intravenous drip paclitaxel weekly, 60mg each time during radiotherapy. 23 cases of radiotherapy alone radiotherapy alone. Results Tet and paclitaxel had the same radiosensitization effect, the total effective rate of both was higher than radiotherapy alone, the difference was statistically significant (P <0.05). The total incidence of radiation pneumonitis in Tet group was significantly lower than the other two groups (P <0.05). In Tet group, the one-year disease-free survival rate was higher than the other two groups. Conclusion Tet has a comparable radiosensitization effect of paclitaxel and can reduce adverse reactions of radiotherapy.